BioNTech SE Sponsored ADR $BNTX Shares Acquired by Groupama Asset Managment

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Groupama Asset Managment boosted its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 126.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 196,544 shares of the company's stock after buying an additional 109,819 shares during the period. Groupama Asset Managment owned 0.08% of BioNTech worth $18,662,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BNTX. Geode Capital Management LLC boosted its stake in BioNTech by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 101,715 shares of the company's stock worth $11,590,000 after buying an additional 1,063 shares during the last quarter. Raymond James Financial Inc. acquired a new position in BioNTech during the fourth quarter worth $584,000. Marshall Wace LLP boosted its stake in BioNTech by 32.9% during the fourth quarter. Marshall Wace LLP now owns 150,157 shares of the company's stock worth $17,108,000 after buying an additional 37,177 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in BioNTech by 63.5% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 7,791 shares of the company's stock worth $887,000 after buying an additional 3,025 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in BioNTech by 61.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock valued at $214,000 after purchasing an additional 713 shares during the period. Institutional investors and hedge funds own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on BNTX shares. The Goldman Sachs Group started coverage on BioNTech in a research report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 target price on the stock. Citigroup restated a "buy" rating and issued a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Morgan Stanley lifted their target price on BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 10th. HC Wainwright reduced their target price on BioNTech from $138.00 to $136.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th. Finally, Wells Fargo & Company set a $150.00 target price on BioNTech and gave the company an "overweight" rating in a research report on Tuesday, August 5th. Thirteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $135.80.

BioNTech Trading Up 0.1%

Shares of BNTX stock traded up $0.11 on Friday, hitting $110.88. The stock had a trading volume of 401,202 shares, compared to its average volume of 701,675. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. The firm has a market capitalization of $26.66 billion, a P/E ratio of -69.30 and a beta of 1.23. BioNTech SE Sponsored ADR has a 1 year low of $81.20 and a 1 year high of $131.49. The company's 50 day moving average price is $109.90 and its 200-day moving average price is $105.38.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company had revenue of $306.46 million for the quarter, compared to analysts' expectations of $161.26 million. During the same quarter last year, the company earned ($3.36) EPS. BioNTech's revenue for the quarter was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. Analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.